Clinical Trials
112 trialsOxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
OPTICAL
Sun Yat-sen University
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
TRIBE-C
Sun Yat-sen University
MK-3475-C66
Merck Sharp & Dohme LLC
HERIZON-GEA-01
Jazz Pharmaceuticals
PREOPANC-3
Erasmus Medical Center
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
PHITT
University of Birmingham
KEYNOTE 975
Merck Sharp & Dohme LLC
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
STAR-221
Arcus Biosciences, Inc.
Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NEO-IMPACT
Australasian Gastro-Intestinal Trials Group
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
National Cancer Institute (NCI)
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Eastern Cooperative Oncology Group
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Spotlight
Astellas Pharma Inc
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
MK-3475-992
Merck Sharp & Dohme LLC
Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
EDGE-Gastric
Arcus Biosciences, Inc.
RASolute 302
Revolution Medicines, Inc.
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
M.D. Anderson Cancer Center
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Takeda
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Providence Health & Services
Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma
Memorial Sloan Kettering Cancer Center
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Sun Yat-sen University
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
LyRICX
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ILUSTRO
Astellas Pharma Inc
Toco-CoR
Vejle Hospital
ARC-25
Arcus Biosciences, Inc.
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Roswell Park Cancer Institute
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Akeso
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
M.D. Anderson Cancer Center
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center